>>WALTHAM, Mass., Sept. 24 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that sales of combination drug therapies for type 2 diabetes, such as GlaxoSmithKline's metformin/rosiglitazone and Bristol-Myers Squibb's metformin/glipizide and metformin/glyburide will increase at a vigorous annual rate of 24%, capturing 16% of the type 2 diabetes market in 2011. This growth rate will bring sales of combination drug therapies in the major pharmaceutical markets (the United states, France, Spain, Italy, Germany, United Kingdom, and Japan) for type 2 diabetes from $335 million in 2001 to nearly $2.9 billion in 2011, according to a new Pharmacor report entitled Type 2 Diabetes. The report also forecasts that PPAR-gammas will add significantly to the market, with a growth rate of 10.6% per year, bringing sales of this class from $1.9 billion in 2001 to $3.1 billion in 2006.
"The type 2 diabetes market will double to $17.2 billion in 2011, reflecting sustained, robust annual growth of 7% from 2001 through 2011," said Carole deDios, analyst at Decision Resources. "Much of this growth will be from single-pill combinations, which improve ease of dosing, and from PPAR- gammas, which will become even more popular with physicians as they increasingly learn how to manage patients with these agents."
Disease Background-Type 2 Diabetes
Type 2 diabetes is a progressive disease of metabolic dysregulation characterized by insulin resistance and impaired insulin secretion. Prolonged lack of control over glucose levels often results in debilitating complications. The International Diabetes Foundation recently warned that type 2 diabetes has become a global pandemic and one of the most challenging public health problems of the 21st century. Because of the chronic and insidious nature of the disease after onset, patients' quality of life is severely affected, and the medical costs can be substantial.<<
snip
Cheers, Tuck |
